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Background and aims: Elevated plasma asymmetric dimethylarginine (ADMA) levels have been observed in
patients with insulin resistance and diabetes, and have been reported to predict adverse cardiovascular events in
type 2 diabetic patients. However, the relationship between ADMA and glycemic control in patients with type 2
diabetes remained controversial.
Methods and results: We evaluated 270 patients with type 2 diabetes and measured their plasma ADMA and
hemoglobin A1c (HbA1c) levels by high performance liquid chromatography. The mean age was 67 ± 12 years. The
mean plasma ADMA and HbA1c level were 0.46 ± 0.09 μmol/l and 7.8 ± 1.6%, respectively. There was no significant
correlation between plasma ADMA level and HbA1c level (r = −0.09, p = 0.13). During the median follow-up period
of 5.7 years (inter-quartile range: 5.0 − 7.3 years), major adverse cardiovascular event (MACE, including cardiovascular
death, myocardial infarction and stroke) was observed in 55 patients (20.4%). Multivariate Cox regression analysis
revealed that the ADMA tertile was an independent risk factor for MACE (ADMA tertile III versus ADMA tertile I:
p = 0.026, HR: 2.31, 95% CI: 1.10 − 4.81). The prognosis predictive power of ADMA disappeared in patients with well
glycemic control (HbA1c ≤6.5%), and the ADMA-HbA1c interaction p value was 0.01.
Conclusions: In patients with type 2 diabetes, ADMA might be an independent risk factor for long-term adverse
cardiovascular events. However, ADMA was not correlated with serum HbA1c level, and in diabetic patients with
HbA1c ≤6.5%, elevated ADMA level was no longer associated with increased risk of long-term prognosis. Our
findings suggested that the prognosis predictive value of ADMA in type 2 diabetes might be modified by the
glycemic control.
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Cardiovascular disease is the major cause of mortality
and morbidity for individuals with type 2 diabetes [1].
Endothelial dysfunction is present from the onset of type 2
diabetes and strongly related to its cardiovascular outcomes
[2], and itself may lead to the development of insulin re-
sistance and diabetes [3,4]. Asymmetric dimethylarginine
(ADMA) is characterized as a circulating endogenous
inhibitor of nitric oxide (NO) synthase by competing
with L-arginine as the substrate [5,6]. Moreover, ADMA* Correspondence: tmlu@vghtpe.gov.tw
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unless otherwise stated.may increase oxidative stress by uncoupling the electron
transport between NO synthase and L-arginine, which can
lead to decrease in the production and availability of
endothelium-derived NO [7,8]. Therefore, derangement of
the L-arginine- NO pathway and increase of oxidative
stress by ADMA have been implicated as important
contributing factors for the development of endothelial
dysfunction. Elevated plasma ADMA levels have been
observed in patients with insulin resistance and type 1/2
diabetes [9-11], and have been reported to be associated
with micro/macrovascular diabetic complications [12-14].
Although several prospective studies have demonstra-
ted that elevated plasma ADMA level may predict ad-
verse cardiovascular events in type 1/2 diabetic patients
[15-17], some other studies showed conflicting results. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and hyperglycemic control in patients with type 2 dia-
betes remained controversial [20,21]. An acute reduc-
tion of plasma ADMA levels by insulin infusion was
demonstrated in young patens with type 1 diabetes [22],
but the same group reported a paradoxical inverse associ-
ation between blood sugar control (glycosylated hemog-
lobin, HbA1c) and ADMA [21]. Hence, although ADMA
appears to be a novel pathogenic factor of diabetes, these
evidences suggest that the interactions among ADMA and
type 2 diabetes are complex and far from being completely
understood. In the present study we aimed to investigate
the relation between plasma ADMA levels and glycemic
control, and evaluate their associations with long-term
clinical outcomes in patients with type 2 diabetes.
Methods
Study population
From July 2006 to June 2009, 270 patients with type
2 diabetes were recruited at Taipei Veterans General
Hospital. Exclusion criteria included patients with severe
liver disease and end-stage renal disease, active infectious
disease, chronic or acute inflammatory disease, malig-
nancy, and unstable hemodynamic status. Thorough me-
dical histories of all participants were recorded. Type 2
diabetes mellitus was diagnosed according to the diagnos-
tic criteria defined by the American Diabetes Association
in 2003 [23] or when the individual was receiving oral
hypoglycemic agents or insulin injection therapy at the
time of recruitment. All of the diabetic patients have
medication with oral hypoglycemic agents (n = 203, 75.2%,
including metformin, n = 159, 58.9%, sulfonylurea, n = 130,
48.1%, thiazolidinedione, n = 18, 6.7%, acarbose, n = 32,
11.9%), and the remaining patients receiving insulin the-
rapy only (n = 44, 16.3%), or insulin combined with oral
hypoglycemic agents (n = 23, 8.5%), while a few received
only dietary therapy only (n = 14, 5.2%). Hypertension
was diagnosed according to the Seventh Joint National
Committee criteria [24] or if the patient was receiving
anti-hypertensive drugs. Patients were considered to have
significant coronary artery disease (CAD) in the presence
of ≥50% stenosis in at least one major coronary artery
by coronary angiography. All medications, cigarette smo-
king and beverages containing alcohol or caffeine were
withdrawn for at least 12 hours. Fasting blood samples
were collected in EDTA tubes for the measurements of
L-arginine, dimethylarginines, HbA1c and for other
biochemical analyses. All patients were prospectively
followed by monthly office visit or by telephone contact
and chart review for the occurrence of the first-ever
major adverse cardiovascular events (MACE) which is
defined as cardiovascular death, stroke and non-fatal
myocardial infarction. Cardiovascular death was diag-
nosed as any death with definite cardiovascular causeor any death that was not clearly attributed to a non-
cardiovascular cause. Myocardial infarction was defined
as the presence of significant new Q waves in at least 2
electrocardiographic leads or of symptoms compatible
with myocardial infarction associated with increase in
creatine kinase-MB fraction ≥3 times the upper limit of
the reference range. Stroke was diagnosed by a neurolo-
gist on the basis of with new neurological deficit or im-
aging study. The study protocol was approved by the
Institutional Review Board at Taipei-Veterans General
Hospital and all participants provided written informed
consent.
Laboratory measurements
Blood samples were centrifuged at 3000 rpm 4°C for 10
minutes immediately after collection and plasma was
frozen at-80°C until analysis. Plasma L-arginine, ADMA
and symmetric dimethylarginine (SDMA) concentrations
were determined by high performance liquid chromatog-
raphy as described previously [25]. The recovery rate for
ADMA was >90% and the within-assay and between-assay
variation coefficients were not more than 7% and 8%, re-
spectively. HbA1c was determined by cation-exchange
high performance liquid chromatography using an auto-
analyzer (Model HLC-G8, Tosoh, Tokyo, Japan). The body
mass index (BMI) was obtained from the ratio of weight
(kg) to height squared (m2). The estimated glomerular
filtration rate (eGFR) was calculated according to the
simplified version of the Modification of Diet in Renal
Disease Study prediction equation formula, modified by
Ma et al. for Chinese patients (eGFR =175 × plasma
creatinine-1.234 × age-0.179 × 0.79 [if female]) [26].
Statistical analysis
Continuous data are presented as the mean ± standard de-
viation or with confidence interval (CI) of 95%. The study
population was divided into two groups according to the
HbA1c concentration > or ≤6.5% or grouped into tertiles
according to the plasma levels of ADMA. All and dif-
ferences between groups were compared with two-sample
t-tests or one-way analysis of variance (ANOVA). Catego-
rical data were compared by Chi-square test or Fisher’s
exact test. Pearson’s correlation coefficients were calcu-
lated to examine possible correlations between continuous
variables. Actuarial event-free survival curves were esti-
mated using the Kaplan-Meier method and compared by
log-rank test. The multivariate Cox regression analysis
was performed to determine the association with the
risk of MACE in all subjects, and the variables tested
included age, gender, body mass index (BMI), hyperten-
sion, ADMA, L-arginine, HbA1c, and serum creatinine
level. The plasma ADMA level was tested as a continu-
ous or categorical variable. To investigate the possibility
of a differential effect of diabetic control in more detail,
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categorical variables (HbA1c ≤6.5% versus HbA1c >6.5%)
and ADMA tertile. The hazards ratio (HR) and 95% confi-
dence interval (CI) were calculated. A p value of less than
0.05 was considered statistically significant. The SPSS 17.0
(SPSS Inc., Chicago, Illinois) software package was used
for statistical analysis.
Results
Baseline characteristics of the study population
The mean age of the 270 patients was 67 ± 12 years,
and most of the patients were male (n = 213, 78.9%)
and had concomitant CAD (n = 211, 78.1%). The mean
plasma ADMA level, SDMA level and L-arginine level
were 0.46 ± 0.09 μmol/l, 0.76 ± 0.42μmol/l and 87.5 ±
29.4 μmol/l, respectively, and the mean HbA1c level
was 7.8 ± 1.6%. Significant correlations were observed be-
tween plasma ADMA level and age (r = 0.21, p < 0.01),
creatinine (r = 0.34, p < 0.01), SDMA (r = 0.44, p < 0.01),Table 1 Clinical characteristics of study population grouped b
Tertile I
n = 90
Age (years) 63 ± 12
Gender (men,%) 73 (81)
BMI (Kg/m2) 27 ± 3
Hypertension (%) 78 (87)
Smoking (%) 22 (24)
Hypercholesterolemia (%) 40 (44)
CAD (%) 66 (73)
Cholesterol (mg/dl)
Total 166 ± 31
HDL-Cholesterol 40 ± 11
LDL-Cholesterol 100 ± 27
Triglyceride (mg/dl) 167 ± 92
Creatinine (mg/dl) 1.1 ± 0.4
eGFR (ml/min per 1.73 m2) 79 ± 28
Fasting blood sugar (mg/dl) 137 ± 54
ADMA (μmol/l) 0.37 ± 0.04
SDMA (μmol/l) 0.60 ± 0.18
L-arginine (μmol/l) 80 ± 26
L-arginine/ADMA 216 ± 72
HbA1c 7.7 ± 1.7
Hypoglycemic treatments
Sulfaurea (%) 42 (47)
Metformin (%) 63 (70)
TZD (%) 6 (7)
Acarbose (%) 12 (13)
Insulin (%) 16 (18)
Insulin + OHA (%) 6 (7)
BMI: body mass index; CAD: coronary artery disease; eGFR: estimated glomerular filL-arginine (r = 0.22, p < 0.01) and eGFR (r = −0.28, p < 0.01),
respectively. In contrast, there was no significant corre-
lation between plasma ADMA level and HbA1c concen-
tration (r = −0.09, p = 0.13). Notably, the plasma ADMA
levels of patients receiving metformin were significantly
lower than those without (0.45 ± 0.08 μmol/l vs 0.48 ±
0.09 μmol/l, p < 0.01). Furthermore, there was a trend
toward higher plasma ADMA level in patients receiving
insulin therapy (p = 0.07). The baseline characteristics of
patients grouped according to ADMA tertiles are shown
in Table 1. There were no significant differences in base-
line clinical parameters among the three groups, with the
exception that the patients in higher ADMA tertiles were
older and had worse renal function (Table1).
Long-term outcome and dimethylarginines
All patients were followed up completely for a median
period of 5.7 years (inter-quartile range: 5.0 − 7.3 years).
During the follow-up period, MACE was observed in 55y ADMA tertile
Tertile II Tertile III
n = 90 n = 90 P value
68 ± 11 70 ± 11 < 0.01
67 (74) 73 (81) 0.51
27 ± 5 27 ± 4 0.45
71 (79) 76 (84) 0.39
16 (18) 15 (17) 0.40
40 (44) 40 (44) 1.00
69 (77) 76 (84) 0.18
163 ± 35 157 ± 31 0.19
40 ± 8 41 ± 14 0.13
101 ± 31 93 ± 25 0.82
155 ± 96 166 ± 102 0.68
1.2 ± 0.4 1.8 ± 1.7 <0.01
70 ± 30 57 ± 33 <0.01
139 ± 51 136 ± 42 0.90
0.45 ± 0.02 0.56 ± 0.06 <0.01
0.69 ± 0.25 0.99 ± 0.60 <0.01
89 ± 28 94 ± 32 0.01
197 ± 64 169 ± 57 <0.01
8.0 ± 1.6 7.8 ± 1.4 0.50
47 (52) 49 (46) 0.65
48 (53) 48 (53) 0.04
6 (7) 6 (7) 1.0
14 (16) 3 (7) 0.16
23 (26) 28 (31) 0.11
11 (12) 6 (7) 0.35
tration rate; OHA: oral hypoglycemic agent; TZD: thiazolidinedie.
Table 2 Clinical characteristics of study population
grouped by glycemic control
HbA1c ≤6.5% HbA1c >6.5%
n = 50 n = 220 P value
Age (years) 68 ± 12 67 ± 12 0.66
Gender (men,%) 40 (80) 173 (79) 0.85
BMI (Kg/m2) 27 ± 4 27 ± 4 0.60
Hypertension (%) 43 (86) 182 (83) 0.67
Smoking (%) 7 (14) 46 (21) 0.33
Hypercholesterolemia (%) 19 (38) 101 (46) 0.35
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(13.3%), 16 non-fatal MI (6.0%) and 7 stroke (2.6%).
The plasma ADMA levels in patients who developed
MACE were significantly higher than in those who did
not (0.49 ± 0.09 μmol/l versus 0.45 ± 0.09 μmol/l, p = 0.006).
By Kaplan-Meier analysis, event-free survival from MACE
was significantly associated with ADMA tertiles (p < 0.005),
with outcome being the worst in those patients with the
highest plasma ADMA levels (Figure 1).
In multivariate Cox regression analysis adjusted for
age, sex, BMI, HbA1c, L-arginine, hypertension and serum
creatinine level, patients in the highest ADMA tertile was
independently associated with a 2.31-fold increased risk
for MACE when compared with patients with the lowest
ADMA tertile (p = 0.026, HR: 2.31, 95% CI: 1.10 − 4.81).
When considering the plasma ADMA level as a continu-
ous variable, the plasma ADMA level remained a signifi-
cant independent predictor for the occurrence of MACE,
and the relative risk of MACE increased by 30% when
plasma ADMA level increased by 1 SD of value (p = 0.04,
HR: 1.30, 95% CI: 1.01 − 1.68).
The plasma SDMA level was significantly associated
with long-term MACE in uni-variate analysis (p < 0.01,
HR: 1.30, 95% CI: 1.14 − 1.48). However, when we put both
ADMA and SDMA into the multivariate Cox regression
analysis, the significance of SDMA disappeared (p = 0.21).
The relationship between ADMA and the control of DM
To investigate the relationship of diabetic control and
ADMA, we divided all patients into those with plasmaFigure 1 Kaplan-Meier survival analyses for major adverse
cardiovascular event during follow-up according to the plasma
ADMA tertiles. P values by log-rank test are shown.HbA1c level ≤6.5% (n = 50) and >6.5% (n = 220). The base-
line characteristics of both groups are shown in Table 2.
The plasma ADMA level of both groups were similar, and
there were no significant differences in baseline clinical
parameters between the two groups, with the exception
that the patients with better diabetic control received less
sulfaurea and insulin treatment, and had higher HDL and
lower triglyceride levels (Table 2).
Table 3 showed the MACE rate stratified according to
the ADMA tertiles and HbA1c level. By Kaplan-Meier
analysis, the higher plasma ADMA tertiles were still associ-
ated with increased risk of MACE in subgroup with serum
HbA1c >6.5%, but not in subgroup with HbA1c ≤6.5%
(Figure 2A, B). In multivariate analysis, ADMA remained
an independent significant predictor for MACE in sub-
group with HbA1c >6.5% (tertile III versus tertile I:
p = 0.02, HR: 3.0, 95% CI: 1.2 − 7.7; ADMA as a conti-
nuous variable: p = 0.04; HR per increase of 1 SD: 1.38,CAD (%) 36 (72) 175 (80) 0.26
Cholesterol (mg/dl)
Total 159 ± 33 164 ± 33 0.39
HDL-Cholesterol 44 ± 16 40 ± 9 0.04
LDL-Cholesterol 95 ± 27 99 ± 29 0.40
Triglyceride (mg/dl) 138 ± 68 170 ± 105 0.04
Creatinine (mg/dl) 1.4 ± 1.0 1.4 ± 1.1 0.96
eGFR (ml/min per 1.73 m2) 69 ± 29 69 ± 32 0.88
Fasting blood sugar (mg/dl) 113 ± 25 143 ± 51 <0.01
ADMA (μmol/l) 0.47 ± 0.10 0.46 ± 0.08 0.27
SDMA (μmol/l) 0.70 ± 0.37 0.81 ± 0.60 0.33
L-arginine (μmol/l) 87 ± 30 88 ± 29 0.83
L-arginine/ADMA 188 ± 69 195 ± 67 0.52
HbA1c 6.1 ± 0.3 8.2 ± 1.5 <0.01
Hypoglycemic treatments
Sulfaurea (%) 17 (34) 113 (51) 0.03
Metformin (%) 29 (58) 130 (59) 1.00
TZD (%) 1 (2) 17 (8) 0.21
Acarbose (%) 2 (4) 30 (14) 0.09
Insulin (%) 5 (10) 62 (28) <0.01
Insulin + OHA (%) 1 (2) 22 (10) 0.09
BMI: body mass index; CAD: coronary artery disease; eGFR: estimated
glomerular filtration rate; OHA: oral hypoglycemic agent; TZD: thiazolidinedie.
Table 3 Major adverse cardiovascular events during
clinical follow-up – stratified according to ADMA tertiles
and glycemic control
ADMA Tertiles
Tertile I Tertile II Tertile III p value*
HbA1c ≤6.5% (n = 50) 4 (18.2%) 2 (25.0%) 3 (15.0%) 0.82*
HbA1c >6.5% (n = 220) 6 (8.8%) 15 (18.3%) 25 (35.7%) <0.001*
MACE: major adverse cardiovascular events, including cardiovascular death,
non-fatal myocardial infarction and stroke; *p value by log-rank test.
Figure 2 Kaplan-Meier survival analyses for major adverse
cardiovascular event during follow-up according to the plasma
ADMA tertiles in subgroup with HbA1c >6.5% (A) and subgroup
with HbA1c ≤6.5% (B). P values by log-rank test are shown.
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(Table 4). There was a significant interaction between the
predictive power of ADMA tertiles for the MACE risk
and diabetic control (interaction p = 0.01). In contrast, gly-
cemic control was not associated with long-term cardio-
vascular outcomes (HbA1c ≤6.5% versus HbA1c >6.5%:
p = 0.57 by log-rank test).
Discussion
The results of this study showed that plasma ADMA
level was a significant independent risk factor for long-
term adverse cardiovascular events in patients with type
2 diabetes, especially in patients with serum HbA1C >6.5%.
In contrast, ADMA was not correlated with serum HbA1c
level. Furthermore, in type 2 diabetic patients with well gly-
cemic control, higher plasma ADMA level was not associ-
ated with higher risk of long-term MACE. Our findings
suggested that the predictive power of ADMA in type 2
diabetes might be modified by the glycemic control.
It is well recognized that type 2 diabetes and its me-
tabolic derangements such as hyperinsulinemia, hyper-
glycemia, dyslipidemia, and increased oxidative stress
are associated with NO-mediated endothelial dysfunc-
tion [2]. In contrast, endothelial dysfunction may lead to
attenuated glucose uptake in insulin-sensitive tissues,
hyperglycemia, and ultimately to the development of in-
sulin resistance and type 2 diabetes [3,4]. Furthermore,
impaired NO bioavailability plays a pivotal role in the
regulation of glucose-stressed endothelial progenitor
cell dysfunction in type 2 diabetes, and anti-oxidant treat-
ment with superoxide dismutase may restore their func-
tion [27]. ADMA, an endogenous competitive inhibitor
of NO synthase, is known to impair NO bioavailability
and endothelial function [5-8]. Over-expression of dime-
thylaminohydrolase (DDAH, the enzyme responsible for
the elimination of ADMA in human) may lead to reduced
plasma ADMA level and enhance insulin sensitivity [28].
In human studies, insulin resistance is related to plasma
ADMA concentration and treatment with rosiglitazone
and weight reduction enhance insulin sensitivity and
significantly lower plasma ADMA level [9,29]. Plasma
ADMA level has been reported to be correlated to
treadmill stress test derived outcome parameters [30] and
asymptomatic carotid atherosclerosis [31]. In pre-diabeticsubjects, elevated ADMA was strongly associated with
increased arterial stiffness, which is a well-established
predictor of cardiovascular outcomes [32]. Furthermore,
plasma ADMA level might predict the future deterior-
ation of glucose tolerance during 4.5-year follow-up inde-
pendent of baseline insulin resistance [33]. Several studies
have showed that the ADMA concentrations might be in-
creased in patients with diabetes [9-11]. Elevated ADMA
level was reported to be associated with the development
Table 4 Univariate and multivariate Cox regression analyses for major adverse cardiovascular events
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age (years) 1.05 (1.02 – 1.08) <0.01 1.05 (1.02 – 1.07) <0.01
Gender 1.89 (0.85 – 4.17) 0.12 - -
BMI 0.96 (0.89 –1.02) 0.20 - -
Hypertension 0.94 (0.47 – 1.86) 0.80 - -
Creatinine 1.10 (0.95 – 1.28) 0.20 - -
HbA1c 1.05 (0.89 – 1 .23) 0.58 - -
Hypercholesterolemia 0.69 (0.40 – 1.12) 0.18 - -
Smoking 0.62 (0.28 – 1.37) 0.24 - -
SDMA 1.30 (1.14 − 1.48) <0.01 - -
L-arginine 0.99 (0.98 – 1.00) 0.12 - -
ADMA
Tertile II versus tertile I 1.64 (0.75 – 3.60) 0.21 1.33 (0.60 – 2.93) 0.48
Tertile III versus tertile I 2.99 (1.45 – 6.16) <0.01 2.31 (1.11 – 4.81) 0.026
HbA1c ≤6.5%
ADMA tertile III vs I 0.62 (0.14 – 2.83) 0.54
HbA1c >6.5%
ADMA tertile III vs I 3.33 (1.35 – 8.26) <0.01
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as worse long-term cardiovascular prognosis in diabetic
patients [15-17]. Furthermore, ADMA was associated
with the coronary atherosclerosis and its extent and se-
verity both in non-diabetic and diabetic patients [34,35].
However, in a large-scale study of 3238 individuals sche-
duled for coronary angiography, the plasma ADMA
levels of patients with type 2 diabetes were only mar-
ginally higher than those of the patients without dia-
betes (0.83 μmol/l versus 0.82 μmol/l, p = 0.032) [36]. In
another large community-based population study en-
rolling 3320 Framinghan Offspring Study participants,
the mean plasma ADMA level was similar between non-
diabetic and diabetic subjects (0.546 μmol/l versus 0.553
μmol/l, p =NS). Furthermore, though in whole population
plasma ADMA level was associated with all-cause mortal-
ity during a follow-up period of 10.9 years, it is surprising
to find that this association was not evident in subgroup
with diabetes [19]. A recent study involving 783 older type
2 diabetic patients showed that plasma ADMA level was
not associated with glycemic control and incident cardio-
vascular disease during the follow-up period of 4 years
[37]. Interestingly, Sibal et al. reported recently that the
plasma ADMA levels in patients with early type 1 diabetes
without macrovascular disease or macroalbuminuria were
even significantly lower compared to healthy controls. In
addition, the plasma ADMA levels were not associated
with impaired flow-mediated dilatation of brachial arteries
in these diabetic patients [38]. Our study showed that
plasma ADMA level was a significant independent risk
factor for long-term adverse cardiovascular events onlyin type 2 diabetic patients with poor glycemic control
(namely in patients with serum HbA1c >6.5%). As the
mean values of HbA1c of diabetic patients in most of
the previous studies showing that ADMA was a prog-
nostic marker in diabetes were >7.0%, the results of our
study might partially explain the conflicting results of
previous studies, suggesting that the involvement of
ADMA in the pathogenesis of diabetes and its predict-
ing value of long-term prognosis might be evident only
in patients with advanced/complicated diabetes as well
as without intensive glycemic control. It has been spec-
ulated that inhibition of uncoupled endothelial NO syn-
thase by ADMA with resulting paradoxical reduction of
oxidative stress might be a possible explanation for the
paradoxical association of ADMA with cardiovascular
events in patients with uncomplicated diabetes [39],
and maybe also in patients with intensive glycemic con-
trol. On the other hand, intensive glycemic control was
not associated with less long-term adverse events in
our study and in other large trial, and even associated with
higher cardiovascular mortality rate in the ACCORD
study [40-42]. Hypoglycemia associated with intensive
glycemic control and other unknown mechanisms might
attenuate the prognosis predictive power of ADMA. Ne-
vertheless, the relation between ADMA and diabetes/
glycemic control seems to be more complex and remains
to be elucidated.
The relationship between ADMA and diabetic control
is not clear. Some studies showed that plasma concen-
trations were inversely correlated with HbA1c in pa-
tients with type 1/2 diabetes [18,20]. In contrast, an
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demonstrated in 15 young patients with type1 diabetes
[22]. Confusingly, Devangelio et al. showed that plasma
ADMA level positively correlated with HbA1c and oxi-
dative stress [20]. Another small study in type 2 dia-
betes showed higher ADMA concentrations in patients
with poor glycemic control (HbA1c >6.5%) [43]. In addi-
tion, intensive treatment of hyperglycemia was associated
with improvement of endothelial dysfunction and de-
crease of plasma ADMA levels [44]. On the other hand,
Krzyzanowska et al. reported that in 125 patients with
type 2 diabetes the plasma ADMA concentrations was
not correlated with HbA1c [15]. In other two larger
cross-sectional study involving more than 500 type 2
diabetes patients and 783 older type 2 diabetes patients
respectively, both showed a lack of significant correlation
between ADMA and HbA1c [37,45]. It is speculated
that chronic hyperglycemia may increase proteolysis and
plasma ADMA levels concomitantly with reduced ADMA
metabolism by DDAH. To the contrary, hyperfiltration
and increased renal clearance driven by hyperglycemia has
been suggested as the major mechanism responsible for
increased excretion of ADMA and possible inverse cor-
relation with HbA1c [18]. Although a significant nega-
tive correlation between ADMA and eGFR was found,
the plasma ADMA concentration was insignificantly cor-
related with HbA1c in our study. Different study design,
different ethnicity and clinical characteristics of the study
population may lead to these conflicting results, and the
relation between ADMA and glycemic control need fur-
ther studies.
Limitations
Several limitations of this study need to be addressed.
First, this study was a single-center observational study,
and most of the patients had CAD and many concomi-
tant atherosclerotic risk factors in addition to diabetes,
which might have a potential impact on the long-term
outcomes. Second, our sample size was small, especially
the group with intensive glycemic control. Confirmation
of our findings in a cohort involving more patients with
well glycemic control is needed. Third, we evaluate the
relation of baseline ADMA and HbA1c levels with long-
term prognosis, but the long-term glycemic control is
uncertain. Finally, as previous studies have shown that
metformin, thiazolidinedies and insulin may affect the
plasma ADMA levels [9,18], their use for control of
diabetes might result in bias in this study. Although the
use of these hypoglycemic agents were largely compar-
able in the ADMA tertiles subgroups and subgroup of
HbA1c ≤6.5% and >6.5%, with the exceptions that more
use of metformin in patients in the lowest ADMA tertiles
and more use of insulin in the HbA1c >6.5% subgroup, we
cannot exclude completely the effects of these medicationon the results of our study even after the adjustment of
multivariate analysis.
Conclusions
In patients with type 2 diabetes, ADMA might be an in-
dependent risk factor for long-term adverse cardiovas-
cular events. However, ADMA was not correlated with
serum HbA1c level, and in diabetic patients with well
glycemic control, namely HbA1c ≤6.5%, elevated ADMA
level was no longer associated with increased risk of long-
term prognosis. Our findings suggested that the prognosis
predictive value of ADMA in type 2 diabetes might be
modified by the glycemic control.
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